Organization
Rehovot, Israel
2 abstracts
Abstract
A phase 1, multi-center, safety, feasibility, and preliminary efficacy study evaluating a single dose of UNO101 in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies.Org: Soroka - Clalit and Ben Gurion University Medical Center, Beer Sheva, Israel, Beyond Cancer, Rehovot, Israel,
Abstract
Effect of P. gingivalis on osimertinib resistance in EGFR-mutant lung cancer.Org: City of Hope National Medical Center, Duarte, CA, Weizmann Institute of Science, Rehovot, Israel, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research,